Workflow
Eyebright Medical(688050)
icon
Search documents
爱博医疗: 688050爱博医疗 关于召开2025年半年度业绩说明会的公告
Zheng Quan Zhi Xing· 2025-08-27 14:02
★ 跟踪:上证科创板100指数 近五日涨跌:3.41% 市盈率: 219.72倍 证券代码:688050 证券简称:爱博医疗 公告编号:2025-048 爱博诺德(北京)医疗科技股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: ? 会议召开时间:2025 年 9 月 4 日(星期四)11:00-12:00 ? 会议召开地点:上海证券交易所上证路演中心 (网址:https://roadshow.sseinfo.com/) ? 会议召开方式:上证路演中心网络互动 ? 投资者可于 2025 年 8 月 28 日(星期四)至 9 月 3 日(星期三)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司投资者邮箱 (investors@ebmedical.com)进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 爱博诺德(北京)医疗科技股份有限公司(以下简称"爱博医疗"或"公司") 已于 2025 年 8 月 28 日在上海证券 ...
爱博医疗: 688050爱博医疗 2025年半年度募集资金存放与实际使用情况专项报告
Zheng Quan Zhi Xing· 2025-08-27 14:02
Fundraising Overview - The company raised a total of RMB 284,614,308.00, with a net amount of RMB 280,612,310.30 after deducting issuance costs [1][2] - As of June 30, 2025, the balance of the special account for raised funds was RMB 231,078,223.02 [1][2] Fund Management - The company has implemented strict management and usage protocols for the raised funds, adhering to relevant regulations and internal guidelines [1][4] - A tripartite supervision agreement was signed with the sponsor and the bank managing the special account [1][3] Fund Usage - A total of RMB 49,576,527.16 was invested in fundraising projects during the reporting period, with no changes in the purpose of the raised funds [2][4] - The company has not experienced any significant changes in the feasibility of the fundraising projects [2][4] Cash Management - The company has not used any temporarily idle raised funds for cash management during the reporting period [3][4] - A resolution was passed to allow the use of temporarily idle funds for cash management, but as of June 30, 2025, the balance for such management was RMB 0.00 [3][4] Loan to Subsidiary - The company approved a loan of up to RMB 26,000,000.00 to its subsidiary, Jiangsu Tianyan Medical Technology Co., Ltd., for project implementation [3][4] Compliance and Disclosure - The company has complied with all relevant laws and regulations regarding the use of raised funds and has disclosed the usage status in a timely manner [4]
爱博医疗: 爱博医疗2025年度“提质增效重回报”行动方案的半年度评估报告
Zheng Quan Zhi Xing· 2025-08-27 14:02
Core Viewpoint - The report outlines the progress and evaluation of the "Quality Improvement and Efficiency Enhancement Action Plan" for 2025, emphasizing the company's commitment to high-quality development and investor value enhancement. Group 1: Business Performance - The company achieved operating revenue of 786.69 million yuan in the first half of the year, representing a year-on-year growth of 14.72% [1] - The net profit attributable to shareholders was 213.31 million yuan, with a year-on-year increase of 2.53% [2] - The revenue from surgical treatment products, particularly high-end artificial lenses, grew by 8.23%, while revenue from contact lenses increased by 28.89% due to expanded sales channels [1][2] Group 2: Market Expansion and Product Structure - The company has established an overseas sales network covering Europe, Asia, and South America, enhancing its market competitiveness [2] - The company is actively participating in international industry conferences and promotional activities to strengthen recognition among overseas doctors and patients [2] - The company has launched a new silicone hydrogel contact lens, breaking the monopoly of foreign companies in the Chinese market [3] Group 3: Quality Management and Production Capacity - The company has implemented a comprehensive quality control system to prevent potential issues in products and processes [2] - A special team has been formed to optimize the automated production line for contact lenses, aiming to increase production capacity significantly [3] - The company plans to achieve an annual production capacity of 252 million contact lenses and 500 million sets of molds after the completion of new projects [3] Group 4: Innovation and R&D - R&D investment increased by 21.55% year-on-year, accounting for 10.60% of operating revenue, supporting the development of new products and technologies [3][4] - The company applied for 44 patents during the reporting period, with 26 patents granted, enhancing its technological competitiveness [4] - The company is focusing on developing core technologies and protecting intellectual property to maintain its industry leadership [4] Group 5: Governance and Information Disclosure - The company has revised its governance documents to align with new regulations, enhancing its governance structure [6] - The board of directors has been re-elected to ensure continuity and diversity in decision-making [6] - The company emphasizes high-quality information disclosure to improve transparency and investor trust [7] Group 6: Shareholder Returns - The company has distributed cash dividends totaling 241 million yuan since its listing, reflecting its commitment to shareholder returns [8] - A share buyback program has been initiated, with 142,800 shares repurchased at an average price of 140.36 yuan per share [8] - The company aims to explore mechanisms that balance immediate and long-term shareholder interests [8]
爱博医疗(688050) - 688050爱博医疗 关于召开2025年半年度业绩说明会的公告
2025-08-27 13:40
(网址:https://roadshow.sseinfo.com/) 会议召开方式:上证路演中心网络互动 投资者可于 2025 年 8 月 28 日(星期四)至 9 月 3 日(星期三)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司投资者邮箱 (investors@ebmedical.com)进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 爱博诺德(北京)医疗科技股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: 爱博诺德(北京)医疗科技股份有限公司(以下简称"爱博医疗"或"公司") 已于 2025 年 8 月 28 日在上海证券交易所网站(www.sse.com.cn)发布了公司《2025 年半年度报告》。为便于广大投资者更全面深入地了解公司 2025 年半年度经营成 果、财务状况,公司计划于 9 月 4 日(星期四)11:00-12:00 举行 2025 年半年度业 绩说明会(以下简称"说明会"),就投资者普 ...
爱博医疗(688050) - 688050爱博医疗 2025年半年度募集资金存放与实际使用情况专项报告
2025-08-27 13:40
证券代码:688050 证券简称:爱博医疗 公告编号:2025-047 爱博诺德(北京)医疗科技股份有限公司 2025 年半年度募集资金存放与实际使用情况专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 一、募集资金基本情况 (一)募集资金金额及到位时间 根据中国证券监督管理委员会出具的《关于同意爱博诺德(北京)医疗科技 股份有限公司向特定对象发行股票注册的批复》(证监许可〔2025〕774 号), 爱博诺德(北京)医疗科技股份有限公司(以下简称"公司"或"本公司") 2024 年度以简易程序向特定对象发行人民币普通股 3,593,615 股,每股发行价格 79.20 元 , 募 集 资 金 总 额 284,614,308.00 元 , 扣 除 相 关 发 行 费 用 人 民 币 4,001,997.70 元后,实际募集资金净额为人民币 280,612,310.30 元。2025 年 4 月 29 日,信永中和会计师事务所(特殊普通合伙)对本次发行募集资金到位情况进 行了审验,并出具了《爱博诺德(北京)医疗科技股份 ...
爱博医疗(688050) - 爱博医疗2025年度“提质增效重回报”行动方案的半年度评估报告
2025-08-27 13:40
爱博诺德(北京)医疗科技股份有限公司 关于 2025 年度"提质增效重回报"行动方案的 为深入贯彻落实国务院《关于进一步提高上市公司质量的意见》等相关要求, 爱博诺德(北京)医疗科技股份有限公司(以下简称"爱博医疗"或"公司")积 极践行"以投资者为本"的上市公司发展理念,推动公司高质量发展和投资价值提 升,已于 2025 年 4 月 23 日披露了《2025 年度"提质增效重回报"行动方案》(以 下简称"《行动方案》")。 2025 年上半年,公司积极落实《行动方案》中的各项工作,聚焦主营业务发展、 推动创新研发成果转化、强化投资者关系管理,有效传递公司长期投资价值。现将 《行动方案》半年度实施进展及评估情况报告如下: 一、聚焦主业,推动高质量发展 2025 年上半年,公司经营成果取得如下进展: (一)夯实主营业务,经营业绩持续增长 面对复杂多变的国内外形势,公司稳健经营,上半年实现营业收入 78,669.11 万 元,同比增长 14.72%。手术治疗产品中,人工晶状体营业收入同比增长 8.23%,"全 视"多焦人工晶状体、"龙晶"有晶体眼人工晶状体等高端产品增长迅速,占比不断 提升;近视防控产品中,"普诺 ...
爱博医疗2025年上半年净利润同比增长2.53%
Bei Jing Shang Bao· 2025-08-27 13:18
北京商报讯(记者 王寅浩 实习记者 宋雨盈)8月27日,爱博医疗发布公告称,2025年上半年实现营业 收入7.87亿元,同比增长14.72%;归属于上市公司股东的净利润为2.13亿元,同比增长2.53%;归属于 上市公司股东的扣除非经常性损益的净利润为2.04亿元,同比增长2.63%。 ...
爱博医疗(688050) - 2025 Q2 - 季度财报
2025-08-27 13:10
1 / 197 爱博诺德(北京)医疗科技股份有限公司2025 年半年度报告 公司代码:688050 公司简称:爱博医疗 爱博诺德(北京)医疗科技股份有限公司 2025 年半年度报告 爱博诺德(北京)医疗科技股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会董事高级管理人员保证半年度报告内容的真实性、准确性、完整性,不存在 虚假记载、误导性陈述或重大遗漏,并承担个别和连带的法律责任。 二、 重大风险提示 本公司已在本报告中详细阐述在生产经营过程中可能面临的各种风险因素,敬请参阅"第三 节管理层讨论与分析"之"四、风险因素"相关内容。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 五、 公司负责人解江冰、主管会计工作负责人郭彦昌及会计机构负责人(会计主管人员)郭彦 昌声明:保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 七、 是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性陈述,不构成本公司对投资者的承诺,敬请 投资者注意 ...
爱博医疗现6笔大宗交易 合计成交26.60万股
爱博医疗8月25日大宗交易平台共发生6笔成交,合计成交量26.60万股,成交金额1943.40万元。成交价 格均为73.06元,相对今日收盘价折价7.40%。从参与大宗交易营业部来看,机构专用席位共出现在2笔 成交的买方或卖方营业部中,合计成交金额为423.75万元,净买入423.75万元。 进一步统计,近3个月内该股累计发生27笔大宗交易,合计成交金额为1.50亿元。 证券时报·数据宝统计显示,爱博医疗今日收盘价为78.90元,上涨1.52%,日换手率为2.59%,成交额为 3.86亿元,全天主力资金净流出514.78万元,近5日该股累计上涨1.53%,近5日资金合计净流入986.42万 元。 两融数据显示,该股最新融资余额为5.47亿元,近5日减少2121.09万元,降幅为3.73%。(数据宝) 8月25日爱博医疗大宗交易一览 | 成交量 | 成交金 | 成交价 | 相对当日收 | | | | --- | --- | --- | --- | --- | --- | | (万 | 额(万 | 格 | 盘折溢价 | 买方营业部 | 卖方营业部 | | 股) | 元) | (元) | (%) | | | | 1 ...
爱博医疗股价上涨1.52% 大宗交易折价7.40%引关注
Jin Rong Jie· 2025-08-25 16:11
Core Viewpoint - Aibo Medical's stock price increased by 1.52% to 78.90 yuan as of August 25, 2025, with significant trading activity noted [1] Group 1: Stock Performance - Aibo Medical's stock opened at 77.72 yuan, reached a high of 79.11 yuan, and a low of 77.72 yuan, with a trading range of 1.79% on the same day [1] - The total trading volume for the day was 3.86 billion yuan [1] Group 2: Business Overview - Aibo Medical specializes in the research, production, and sales of ophthalmic medical devices, including artificial lenses and orthokeratology lenses [1] - The company operates in sectors such as medical devices and specialized innovation [1] Group 3: Trading Activity - On August 25, Aibo Medical experienced six block trades totaling 266,000 shares, amounting to 19.434 million yuan, with an average transaction price of 73.06 yuan, reflecting a discount of 7.40% compared to the closing price [1] - Institutional accounts purchased 58,000 shares, with a transaction value of 4.2375 million yuan [1] Group 4: Capital Flow - On the same day, Aibo Medical saw a net outflow of 1.6362 million yuan in main funds, while the net inflow over the past five days was 2.6767 million yuan [2]